Interim results for the six months ended 30 Jun 26

AI SummaryClose X

Shield Therapeutics plc reported interim results for the six months ended June 30, 2026, with group revenues reaching $30.4 million, a 42% increase from the prior year, driven by strong growth in the commercially insured patient segment and ex-US milestone and royalty income of $10.3 million. The company significantly narrowed its group loss to $2.3 million, compared to $9.5 million in the same period last year, and remains on track for operating profitability in 2026. ACCRUFeR® prescriptions sold increased to approximately 102,000, up 21% from the previous year, despite changes in New York's Medicaid program, with a notable 27% prescription growth in the commercially insured segment. The company also received a $7.9 million development milestone payment from its Chinese partner, ASK Pharma.

Disclaimer*

UK 100

Latest directors dealings